265 related articles for article (PubMed ID: 23998731)
21. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol.
Quinn MA; Green MJ; Marzo-Ortega H; Proudman S; Karim Z; Wakefield RJ; Conaghan PG; Emery P
Arthritis Rheum; 2003 Nov; 48(11):3039-45. PubMed ID: 14613264
[TBL] [Abstract][Full Text] [Related]
22. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
Sokka T; Pincus T
J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
[TBL] [Abstract][Full Text] [Related]
23. Early rheumatoid arthritis: strategies for prevention and management.
Combe B
Best Pract Res Clin Rheumatol; 2007 Feb; 21(1):27-42. PubMed ID: 17350542
[TBL] [Abstract][Full Text] [Related]
24. [Rheumatoid arthritis (updated Current Care guideline)].
Hakala M; Hannonen P; Helve T; Korpela M; Mattila K; Möttönen T; Varis T;
Duodecim; 2009; 125(19):2131-2. PubMed ID: 19938416
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of rheumatoid arthritis].
Babić-Naglić D
Reumatizam; 2003; 50(2):22-7. PubMed ID: 15098369
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic strategies in early rheumatoid arthritis.
Smolen JS; Aletaha D; Machold KP
Best Pract Res Clin Rheumatol; 2005 Feb; 19(1):163-77. PubMed ID: 15588977
[TBL] [Abstract][Full Text] [Related]
27. Overview of combination second-line or disease-modifying antirheumatic drug therapy in rheumatoid arthritis.
Williams HJ
Br J Rheumatol; 1995 Nov; 34 Suppl 2():96-9. PubMed ID: 8535657
[TBL] [Abstract][Full Text] [Related]
28. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
[TBL] [Abstract][Full Text] [Related]
29. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
[TBL] [Abstract][Full Text] [Related]
30. [Rheumatology update--II. Overview of the clinically important status of knowledge and prospects for possible relevant trends in etiopathogenetic research, diagnostic methods and therapeutic possibilities].
Hein G; Bolwin R; Bräuer R; Eidner T; Franke S; Oelzner P; Sprott H
Med Klin (Munich); 1995 May; 90(5):294-302. PubMed ID: 7791697
[No Abstract] [Full Text] [Related]
31. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Leirisalo-Repo M
Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599
[TBL] [Abstract][Full Text] [Related]
32. High dose chemotherapy and syngeneic stem cell transplantation in a patient with refractory rheumatoid arthritis: poor response associated with persistence of host autoantibodies and synovial abnormalities.
van Oosterhout M; Verburg RJ; Levarht EW; Moolenburgh JD; Barge RM; Fibbe WE; van Laar JM
Ann Rheum Dis; 2005 Dec; 64(12):1783-5. PubMed ID: 16284342
[TBL] [Abstract][Full Text] [Related]
33. Does partial control of inflammation prevent long-term joint damage? Clinical rationale for combination therapy with multiple disease-modifying antirheumatic drugs.
Pincus T; Breedveld FC; Emery P
Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S2-7. PubMed ID: 10589350
[No Abstract] [Full Text] [Related]
34. [New therapeutic strategy of rheumatoid arthritis to reach the goal of suppression of joint destruction].
Yamaguchi Y; Yamamoto K
Clin Calcium; 2007 Apr; 17(4):463-73. PubMed ID: 17404474
[TBL] [Abstract][Full Text] [Related]
35. Clinical experience with inhibition of interleukin-6.
Choy E
Rheum Dis Clin North Am; 2004 May; 30(2):405-15, viii. PubMed ID: 15172049
[TBL] [Abstract][Full Text] [Related]
36. [DMARDs (disease-modifying antirheumatic drugs)].
Tanaka E; Yamanaka H
Nihon Rinsho; 2013 Jul; 71(7):1199-206. PubMed ID: 23961667
[TBL] [Abstract][Full Text] [Related]
37. Immunopathogenic Mechanisms and Novel Immune-Modulated Therapies in Rheumatoid Arthritis.
Chen SJ; Lin GJ; Chen JW; Wang KC; Tien CH; Hu CF; Chang CN; Hsu WF; Fan HC; Sytwu HK
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884802
[TBL] [Abstract][Full Text] [Related]
38. Rheumatoid arthritis.
Lee DM; Weinblatt ME
Lancet; 2001 Sep; 358(9285):903-11. PubMed ID: 11567728
[TBL] [Abstract][Full Text] [Related]
39. Inflammatory immune cell responses and Toll-like receptor expression in synovial tissues in rheumatoid arthritis patients treated with biologics or DMARDs.
Takakubo Y; Tamaki Y; Hirayama T; Iwazaki K; Sasaki K; Sasaki A; Ohki H; Takakubo N; Konttinen YT; Takagi M
Clin Rheumatol; 2013 Jun; 32(6):853-61. PubMed ID: 23397147
[TBL] [Abstract][Full Text] [Related]
40. Cell therapies for refractory rheumatoid arthritis.
Liu R; Zhao P; Tan W; Zhang M
Clin Exp Rheumatol; 2018; 36(5):911-919. PubMed ID: 29745893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
